Concurrent with the merger, the combined company has been renamed Cartesian Therapeutics, Inc. The Company's Nasdaq ticker symbol will change to "RNAC" effective prior to the opening of trading tomorrow, November 14, 2023.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/18/2023 | $1.00 | Outperform → Market Perform | SVB Securities |
| 6/14/2022 | $6.00 → $5.00 | Buy | Needham |
| 6/6/2022 | $7.00 | Outperform | SVB Leerink |
| 11/1/2021 | $6.00 → $7.00 | Buy | Needham |
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00
Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $5.00 from $6.00 previously
SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00
WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022. "Blaine is a highly accomplished biopharmaceutical executive with proven financial and business development expertise," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "We are preparing for a number of key potential milestones across our pipeline
CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. "I am thrilled to welcome Carsten to the Surface Oncology board," said Rob Ross, M.D., chief executive officer at Surface. "Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we ad
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer. "Kevin's deep financial expertise and experience in the gene therapy and rare disease landscape makes him an ideal fit for Selecta's executive team," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "This is an exciting time for Selecta on the heels of our recent collaboration with Cyrus Biotechnology to unlock a new generation of inno
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen
– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its cli
- Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter
Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last infusion Phase 2 study of Descartes-08 in systemic lupus erythematosus expected to initiate in 1H24 Clinical pipeline expanded following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118M pro forma cash and cash equivalents as of D
Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therap
– Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen
Selecta Biosciences Inc (NASDAQ:SELB) and Cartesian Therapeutics Inc announced a reverse merger in an all-stock deal, with Selecta shareholders owning 26.9% of the new company. In August, Selecta Biosciences provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for chronic refractory gout, which Selecta will continue to support. The combined company has been renamed Cartesian Therapeutics, with the Nasdaq ticker symbol changing to "RNAC," effective before the opening of trading tomorrow, November 14, 2023. The combined company will be led by Selecta's CEO Carsten Brunn and Cartesian co-
Concurrent with the merger, the combined company has been renamed Cartesian Therapeutics, Inc. The Company's Nasdaq ticker symbol will change to "RNAC" effective prior to the opening of trading tomorrow, November 14, 2023.
Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it has entered into an agreement to transition the manufacturing and development rights and remaining clinical operations of ImmTOR for SEL-212 to its development and commercialization partner, Swedish Orphan Biovitrum AB (publ.) (Sobi). As of November 6, 2023, Sobi will assume responsibility for the manufacturing and commercial supply of ImmTOR for SEL-212. SEL-212, a combination of Selecta's ImmTOR immune tolerance platform and a therapeutic uricase enzyme (pegadricase), is in
SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)
DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)
PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)